# 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations

> **NCT00813306** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (estimated)

## Conditions studied

- Reflux Episodes

## Interventions

- **DRUG:** AZD2066
- **DRUG:** Placebo
- **DRUG:** AZD2066
- **DRUG:** AZD2066
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00813306
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** —
- **Final completion:** 2009-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813306, "14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00813306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*